Parkinson's Clinical Trials and Current Research (2024)

In this webinar, Dr. Matthew Deen dives into the latest advancements in Parkinson's disease research. He unravels the fundamentals of clinical trials and their role in evaluating new therapies. Dr.Deen provides insights into cutting-edge treatments like alpha-synuclein and GBA/LRRK2, along with a glimpse into the methods used to measure their effectiveness.

Dr. Matthew Deen, a chemical biologist, is currently engaged in post-doctoral research under Prof. Wennemers at ETH Zurich. Previously, during his doctoral studies under Prof. David Vocadlo at Simon Fraser University, he specialized in developing innovative methods for studying Parkinson's disease (PD) biology. As a key member of Prof. Vocadlo's lab, he applied these methods to identify novel therapies for PD and played a crucial role in developing a groundbreaking clinical diagnostic tool. Dr. Deen's groundbreaking work has garnered support from the Michael J. Fox Foundation and Parkinson Society British Columbia.

**Disclaimer: These sessions are designed to provide general education and are not intended for individual advice and/or clinical care. The information conveyed in this recording was accurate at the time of presentation.**